Celularity Sells Biomaterials Portfolio to NexGel for $13.3M
Event summary
- Celularity closed a $13.3M deal with NexGel, selling its biomaterials portfolio and licensing certain products.
- The transaction included $8.3M in cash and a $5.0M convertible note, with up to $20M in potential milestone payments.
- Celularity used proceeds to retire nearly $13M in debt, strengthening its balance sheet.
- The deal allows Celularity to focus on its longevity-focused therapeutic pipeline and scalable manufacturing platform.
The big picture
Celularity's sale of its biomaterials portfolio to NexGel aligns with a broader industry trend of biotech firms streamlining operations to focus on high-value therapeutic areas. The $13.3M transaction not only strengthens Celularity's financial position but also underscores the strategic shift toward longevity-focused treatments, a rapidly growing segment within regenerative medicine.
What we're watching
- Execution Risk
- Whether Celularity can successfully advance its longevity-focused pipeline after divesting non-core assets.
- Financial Flexibility
- How the strengthened balance sheet will impact Celularity's ability to fund future R&D and strategic initiatives.
- Milestone Payments
- The pace at which NexGel achieves net sales thresholds to trigger Celularity's potential $20M in milestone payments.
Related topics